FDA-cleared profile

NinesAI

Nines, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Provides a parallel triage workflow for head CT images with suspected intracranial hemorrhage and/or mass effect for radiologist prioritization.

Clinical role
Triage tool that automatically analyzes head CT DICOM images as they arrive in PACS for suspected intracranial hemorrhage and/or mass effect and identifies them in a radiologist's worklist; not to be relied on to make or confirm a diagnosis.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Notification only, not diagnostic; requires full evaluation, previews outside the DICOM viewer are informational, and cases remain on the standard worklist.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides a parallel triage workflow for head CT images with suspected intracranial hemorrhage and/or mass effect for radiologist prioritization.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM noncontrast head CT images arriving in PACS.
  • Who uses it?Intended users: Hospital networks, trained clinicians, and radiologists.
  • What does the software produce?Output: Radiologist worklist notifications, optional HL7 messages and DICOM secondary series, and non-diagnostic previews.
  • What is its most important limitation?Key limitation: Notification only, not diagnostic; requires full evaluation, previews outside the DICOM viewer are informational, and cases remain on the standard worklist.

Clinical takeaway. Clinical role: Provides a parallel triage workflow for head CT images with suspected intracranial hemorrhage and/or mass effect for radiologist prioritization.

Evidence takeaway. Evidence from the reviewed source record: Separate retrospective trials at over 20 sites reported ICH sensitivity 0.899, mass-effect sensitivity 0.964, mass-effect specificity 0.911, and notification time 0.23 minutes; the printed ICH specificity interval is internally invalid and is not used.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides a parallel triage workflow for head CT images with suspected intracranial hemorrhage and/or mass effect for radiologist prioritization.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Triage tool that automatically analyzes head CT DICOM images as they arrive in PACS for suspected intracranial hemorrhage and/or mass effect and identifies them in a radiologist's worklist; not to be relied on to make or confirm a diagnosis.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software automatically analyzes Digital Imaging and Communications in Medicine (DICOM) images as they arrive in the Picture Archive and Communication System (PACS) using machine learning algorithms." … "Specifically, the software analyzes head CT images of the brain to assess the suspected presence of intracranial hemorrhage and/or mass effect and identifies images with potential emergent findings in a radiologist’s worklist.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM noncontrast head CT images arriving in PACS.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet input scope.

Output and clinician action
Radiologist worklist notifications, optional HL7 messages and DICOM secondary series, and non-diagnostic previews.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet output scope.

Care setting
Used by hospital networks and trained clinicians on head CT images of the brain to aid radiologists in prioritizing review.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "NinesAI is a parallel workflow tool indicated for use by hospital networks and trained clinicians to identify images of specific patients to a radiologist, independent of standard of care workflow, to aid in prioritizing and performing the radiological review." … "Specifically, the software analyzes head CT images of the brain to assess the suspected presence of intracranial hemorrhage and/or mass effect". Read from the exact FDA decision document on 2026-11-14.

Intended users
Hospital networks, trained clinicians, and radiologists.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet user scope.

Limitations
Notification only, not diagnostic; requires full evaluation, previews outside the DICOM viewer are informational, and cases remain on the standard worklist.
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA limitation boundary.

Evidence summary
Separate retrospective trials at over 20 sites reported ICH sensitivity 0.899, mass-effect sensitivity 0.964, mass-effect specificity 0.911, and notification time 0.23 minutes; the printed ICH specificity interval is internally invalid and is not used.
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported endpoints with an explicitly quarantined invalid interval.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Separate retrospective trials at over 20 sites reported ICH sensitivity 0.899, mass-effect sensitivity 0.964, mass-effect specificity 0.911, and notification time 0.23 minutes; the printed ICH specificity interval is internally invalid and is not used.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Submission-reported endpoints with an explicitly quarantined invalid interval.

Reported sensitivity
89.9% (95% CI: 83.7%, 94.0%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
97.4% (95% CI: 99.4%, 99.2%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

NinesAI-ICH regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K193351
  • Sites20
  • IndependenceIndependence not established

K193351

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K193351. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM noncontrast head CT images arriving in PACS.

    Scope: Exact FDA submission. FDA packet input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K193351: NinesAI

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and HL7 in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · NinesAI-ICH model card (K193351)

  3. AI processing

    Source context, not route validation: The exact FDA package describes NinesAI as a complete software package comprising image analysis software and a workstation module that is used to alert the radiologist. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software system is a complete package comprised of image analysis software and a workstation module that is used to alert the radiologist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K193351: NinesAI

  4. Returned objects

    Source context, not route validation: Radiologist worklist notifications, optional HL7 messages and DICOM secondary series, and non-diagnostic previews.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K193351: NinesAI

  5. Viewer/worklist/report

    Unresolved route: Radiologist worklist notifications, optional HL7 messages and DICOM secondary series, and non-diagnostic previews.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K193351: NinesAI

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes NinesAI as a complete software package comprising image analysis software and a workstation module that is used to alert the radiologist. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software system is a complete package comprised of image analysis software and a workstation module that is used to alert the radiologist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM and HL7 in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Training
The 510(k) summary states NinesAI is a parallel workflow tool indicated for use by hospital networks and trained clinicians to identify images of specific patients to a radiologist, independent of standard of care workflow, to aid in prioritizing and performing the radiological review, and that all radiological studies are still reviewed by trained radiologists.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

workstation is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for NinesAI; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K193351
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA noncontrast head CT scope normalized to controlled CT bucket.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Exact FDA brain scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-04-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K193351 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K193351: NinesAI

    U.S. Food and Drug Administration - Published 2020-04-21 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. NinesAI-ICH model card (K193351)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K193351

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K193351 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history